Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-19

Clinical Trial Update: 24-hour IOP-lowering Effect of 0.01% Bimatoprost [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial reports that 0.01% bimatoprost lowers intraocular pressure over a 24-hour period. The study results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bimatoprost (bimatoprost)

Snippet

Sponsor: University of California, San Diego | Conditions: Intraocular Pressure, Glaucoma | Phase 4 | Status: COMPLETED | Results posted: 2014-06-19